Search
for
Sort by
Research 331–360 of 345
- Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review
- Drug-induced alopecia areata: A systematic review
- What is alopecia areata?
- Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
- Survey of pediatric dermatologist views on treatment for alopecia areata
- Understanding autoimmunity of vitiligo and alopecia areata
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
- Optimization of Gelatin and Crosslinker Concentrations in a Gelatin/Alginate-Based Bioink with Potential Applications in a Simplified Skin Model
- Annular alopecia areata: Report of two cases
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Alopecia Areata: Current Review
- Successful management of severe alopecia areata and vitiligo using topical delgocitinib and a 308-nm excimer laser
- Auditory Threshold Variability in the SAMP8 Mouse Model of Age-Related Hearing Loss: Functional Loss and Phenotypic Change Precede Outer Hair Cell Loss
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- Treatment of Alopecia Areata With Squaric Acid Dibutylester
- Treatment of alopecia areata with squaric acid dibutylester
- Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata
- Topical use of calcipotriol does not potentiate squaric acid dibutylester effectiveness in the treatment of alopecia areata
- Hapten‐induced lymphadenosis benigna cutis secondary to squaric acid dibutylester sensitization for alopecia areata
- Severe pustular lesions induced by topical immunotherapy with squaric acid dibutylester for alopecia totalis
- Squaric Acid Dibutylester Promotes Innate Immune-Driven Hair Growth with CD206+ Macrophage Accumulation in the Dermis
- 965 The importance of CD206+ macrophages in squaric acid dibutylester-induced hair cycle activation
- 440 Squaric acid dibutylester, used in alopecia areata immunotherapy, promotes innate immune-driven hair growth with CD206+ macrophage accumulation in the dermis
- Childhood epidermolysis bullosa acquisita during squaric acid dibutyl ester immunotherapy for alopecia areata
- Angioedema After Squaric Acid Treatment in a 6‐Year‐Old Girl
- Efficacy of topical sensitizers in the treatment of alopecia areata
- Alopecia Areata: Treatment of Today and Tomorrow
- Topical immunotherapy in alopecia areata
- Review of treatment for alopecia totalis and alopecia universalis